| Ticker Details |
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
|
| IPO Date: |
September 7, 2005 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.62B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.40 | 2.11%
|
| Avg Daily Range (30 D): |
$3.36 | 1.74%
|
| Avg Daily Range (90 D): |
$2.90 | 1.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.21M |
| Avg Daily Volume (30 D): |
.17M |
| Avg Daily Volume (90 D): |
.15M |
| Trade Size |
| Avg Trade Size (Sh.): |
71 |
| Avg Trade Size (Sh.) (30 D): |
33 |
| Avg Trade Size (Sh.) (90 D): |
27 |
| Institutional Trades |
| Total Institutional Trades: |
5,534 |
| Avg Institutional Trade: |
$3.16M |
| Avg Institutional Trade (30 D): |
$4.28M |
| Avg Institutional Trade (90 D): |
$4.82M |
| Avg Institutional Trade Volume: |
.03M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.28M |
| Avg Closing Trade (30 D): |
$4.5M |
| Avg Closing Trade (90 D): |
$5.17M |
| Avg Closing Volume: |
29.81K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$2.32
|
$5.99
|
$.25
|
|
Diluted EPS
|
$2.05
|
$5.68
|
$.24
|
|
Revenue
|
$251.23M
|
$115.46M
|
$47.63M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$48.58M
|
$117.27M
|
$4.85M
|
|
Operating Income / Loss
|
$17.52M
|
$54.93M
|
$8.44M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$75.76M
|
$68.89M
|
$22.42M
|
|
PE Ratio
|
92.20
|
|
|
|
|
|
